Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

biote (BTMD) Cash & Equivalents: 2021-2024

Historic Cash & Equivalents for biote (BTMD) over the last 4 years, with FY2024 value amounting to $39.3 million.

  • biote's Cash & Equivalents fell 2662.39% to $28.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.0 million, marking a year-over-year decrease of 2662.39%. This contributed to the annual value of $39.3 million for FY2024, which is 5579.65% down from last year.
  • According to the latest figures from FY2024, biote's Cash & Equivalents is $39.3 million, which was down 5579.65% from $89.0 million recorded in FY2023.
  • In the past 5 years, biote's Cash & Equivalents ranged from a high of $89.0 million in FY2023 and a low of $26.8 million during FY2021
  • In the last 4 years, biote's Cash & Equivalents had a median value of $59.3 million in 2022 and averaged $58.6 million.
  • In the last 5 years, biote's Cash & Equivalents surged by 19601.36% in 2022 and then crashed by 5579.65% in 2024.
  • Annual analysis of 4 years shows biote's Cash & Equivalents stood at $26.8 million in 2021, then soared by 196.01% to $79.2 million in 2022, then rose by 12.33% to $89.0 million in 2023, then plummeted by 55.8% to $39.3 million in 2024.
  • Its Cash & Equivalents was $39.3 million in FY2024, compared to $89.0 million in FY2023 and $79.2 million in FY2022.